Research at EyeCare Partners
Advancing the Field of Eye Care, One Clinical Trial at a Time
EyeCare Partners is committed to innovation and elevating eye care for everyone. ECP is home to world-renowned centers of eye care excellence and leaders from every specialty and subspecialty. The eye doctors and research staff at ECP have been conducting clinical research for more than 35 years and have participated in over 500 research studies. Our goal is to pave the way for tomorrow’s eye care and bring it to our patients today.
The EyeCare Partners practices participate in numerous studies across all subspecialties, these include dry eye, glaucoma, cataracts, macular degeneration, diabetes and more. Explore our current clinical research studies with open enrollment and complete the form to learn more about taking part.
How Does Clinical Research Help Our Patients?
Thousands of patients with eye problems come to an EyeCare Partners practice each week to find leading-edge solutions to their eye care needs. Our participation in clinical research allows us to offer patients the most advanced treatment options possible.
Staying on the Leading Edge of Eye Care Research
Our ongoing commitment to physician-controlled eye care research enables us to:
- Provide patients with new and improved treatment options
- Be at the forefront of vision care advances
- Create an environment for lifelong learning and advancement
- Advance the future of eye health and vision
Clinical Study Sponsors
EyeCare Partners plays an active role in clinical research to advance the future of eye care. Our experienced eye doctors and specialized research teams partner with emerging and established pharmaceutical and biotechnology companies to explore the next generation of ocular treatments. EyeCare Partners has 20+ practices and over 100 Investigators that participate in more than 200 clinical trials and we look forward to continuing our commitment to state-of-the-art clinical research.
What Type of Clinical Research Happens at EyeCare Partners?
Our doctors are always seeking solutions for eye conditions and vision issues. The clinical trials at EyeCare Partners spans Phases 1-4 and a range of specialties. Examples of research topics include:
New and Innovative Ocular Medications
- Dry Eye Medications and Treatments
- Ocular Surface Disease
- Glaucoma Medications
- Wet and Dry Macular Degeneration
- Diabetic Retinopathy
- Diabetic Macular Edema
- Inherited Retinal Disease
- Uveitis
Novel Surgical Procedures, Devices, and Intraocular Implants
- Intraocular Lenses for Cataract Surgery
- Micro-Invasive Glaucoma Devices
- Specialized Corneal Transplantation
- Artificial Iris Devices
- Diabetic Macular Edema
- Wet Macular Degeneration

Meet Our Director of Clinical Research
Megan Kingdon, BSN, RN, COA, CCRC, Director of Clinical Research – EyeCare Partners
Megan Kingdon, Director of Clinical Research at EyeCare Partners, brings more than 20 years of expertise in ophthalmology and clinical research. She spent many of those years at the Cincinnati Eye Institute (CEI), starting as an ophthalmic technician and quickly moving into a clinical research coordinator role in Anterior Segment. She obtained her nursing degree and did a stent in obstetrics at UC Hospital before returning to CEI as the clinical research coordinator for the retina department, where she grew the department from three clinical trials to thirty active trials. In 2021, she became the Director of Clinical Research for CEI Vision Partners in the Retina Department and then following the acquisition by EyeCare Partners, she was made Director of Clinical Research for ECP, overseeing more than 20 practices across the country.
Megan has extensive medical and surgical clinical trial experience in a wide range of ophthalmological conditions, including cataracts and IOLs, artificial iris devices, age-related macular degeneration, diabetic retinopathy, geographic atrophy, macular edema, proliferative vitreo-retinopathy, retinal vein occlusion, vitreomacular traction and inherited retinal diseases. Megan holds a Bachelor’s of Science in biology and chemistry from Lawrence University and a Bachelor’s of Science in nursing from the University of Cincinnati. She is certified by the Association of Clinical Research Professionals.
Why Choose EyeCare Partners For Clinical Research?
Facilities
- State-of-the-art imaging and diagnostic equipment
- Dedicated, visual acuity testing rooms
- Designated monitoring rooms with high speed internet and phone access
Staff
- Experienced and award-winning eye doctors
- Dedicated clinical research coordinators
- Certified Ophthalmic Technicians and Photographers
- Trained personnel for handling/preparing for transportation of dangerous goods
Process
- Adherence to Good Clinical Practice guidelines
- Customized standard operating procedures
- Excellent subject retention
- Direct oversight by the PI and Research Director
Current Clinical Research Studies
Kansas
Stiles EyeCare Excellence
Alcon
THE HYDRUS® MICROSTENT NEW ENROLLMENT POST-APPROVAL STUDY: A PROSPECTIVE, NON-RANDOMIZED, MULTICENTER, SINGLE ARM, CLINICAL TRIAL (CONFIRM)
Glaukos
A Prospective, Multicenter Device Study in Subjects with Primary Open-Angle Glaucoma Who Have Failed Previous Medical and Surgical Treatment
Grene Vision Group
Apthera
IC-8 Apthera IOL New Enrollment Post Approval Study
Missouri
Ophthalmology Associates
Tear Solutions
Dompe
A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle- Controlled, Study to demonstrate Efficacy and Safety of DFL24498 Eye Drop Solution in Adult Participants with Atopic Keratoconjunctivitis (AKC)
YS Life Sciences
A Comparative Randomized, Investigator-Blind, Active-Controlled, Parallel-Group, Multicenter, Clinical Endpoint Study to Evaluate Efficacy and Safety of Bimatoprost Ophthalmic Solution 0.01% (YSBP) of YS Life Science Co., Ltd. (YSLS) and Lumigan® (Bimatoprost Ophthalmic Solution) 0.01% of AbbVie INC, in the Treatment of Subjects with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) in Both Eyes
Harrow
A Phase3, Prospective, Multicenter, Randomized, Parallel-Arm Double-Masked, Placebo-Controlled Study Evaluating the Safety and Efficacy of Triesence for the Treatment of Ocular Inflammation and Pain after Ophthalmic Surgery
Ophthalmology Consultants
Glaukos
Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose® TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone
Kowa
A Multi-Center Prospective Clinical Trial to Investigate the Safety and Effectiveness of the KI-362-US3 (Avansee Preset) for Correction of Aphakia Following Cataract Extraction
Harrow
A Phase3, Prospective, Multicenter, Randomized, Parallel-Arm Double-Masked, Placebo-Controlled Study Evaluating the Safety and Efficacy of Triesence for the Treatment of Ocular Inflammation and Pain after Ophthalmic Surgery
Florida
Eye Institute of West Florida
Glaukos
Multicenter, Randomized, Double-masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Copper Sulfate Ophthalmic Solution in Subjects with Keratoconus
Glaukos
A Randomized, Multicenter, Double-Masked, Vehicle -Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1)
Astellas
A NON-INTERVENTIONAL, OBSERVATIONAL STUDY TO EVALUATE TREATMENT PATTERNS AND SAFETY OF AVACINCAPTAD PEGOL (ACP/IZERVAY™) IN ROUTINE CLINICAL PRACTICE IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Virginia
Virginia Eye Consultants
Novaliq
Phase 2 trial for Non-Infectious Anterior Uveitis in adult patients
Dompe
Phase 3, multicenter, randomized, double-masked, vehicle-controlled, parallel group study to evaluate the safety and efficacy of recombinant human nerve growth factor eye drop solution in participants with persistent corneal epithelial defect (PCED)
Viatris
Phase 1/2, multicenter, open-label, single-dose, first-in-human, dose-escalation trial. A total of up to approximately 30 participants will be enrolled in this trial, which will consist of two parts: Part 1, dose-escalation trial consists of 3 different dose cohorts, and Part 2 consists of an Expansion Cohort.
Glaukos
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1)
Krystal Biotech
A Phase 1/2, multicenter, double-masked, placebo controlled study of KB801 in Subjects with Stage 2 or 3 Neurotrophic Keratitis
Sling
Phase 3, Randomized, Double-mask, Placebo-controlled Study with Open-label Extension to Evaluate the Efficacy and Safety of Linsitinib in Participants with Moderate to Severe Active Thyroid Eye Disease (TED)
Kentucky
Retina Associates of Kentucky
No enrolling trials at this time
Bennett and Bloom
No enrolling trials at this time
Indiana
John Kenyon
No enrolling trials at this time
Ohio
Cincinnati Eye Institute
Genentech
A Phase IIa Multicenter, Open-Label, Single-Arm Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Beacon
A Phase 2/3, Randomized, Controlled, Masked, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501, a Recombinant Adeno-Associated Virus Vector Expressing RPGR (rAAV2tYF-GRK1-RPGR), Compared to an Untreated Control Group in Male Participants
Ascidian
Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Subretinal ACDN-01 in Participants with ABCA4-Related Retinopathy
Genentech
A Phase IIIb/IV, Multicenter, Visual Assessor Masked Study of the Efficacy and Safety of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration Previously Treated with Intravitreal Agents Other than Ranibizumab
Neuracle
A Phase 1/2a Open-Label Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of NG101 AAV Gene Therapy in Subjects with Wet Age-Related Macular Degeneration
Regeneron
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Genentech
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination with Aflibercept or Faricimab in Patients with Diabetic Macular Edema
Alcon
A Phase II, Prospective, Two-Stage, Double-Masked, Randomized, Multi-Center, Controlled, Dose-Response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-17043 and PG043 (AR-17043/Latanoprost) Ophthalmic Solutions in Subjects with Elevated Intraocular Pressure
Samsara
A prospective, multicenter clinical study of the Implantable Miniature Telescope, Model SING in patients with central vision impairment associated with end-stage age-related macular degeneration (AMD)
4DMT
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Neurotech
A Phase 4, Multicenter, Open-label Study to Evaluate Long-term Safety and Efficacy of Revakinagene Taroretcel-Lwey (NT-501) Previously Implanted During a Phase 1, Phase 2, or Phase 3 Clinical Study and to Evaluate NT-501 Implanted in Participants who Underwent the Sham Procedure in a Phase 3 Clinical Study of Macular Telangiectasia Type 2 (MacTel)
SpliceBio
Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
Opus Genetics
A Phase 1b/2a, Open-Label, Dose-Exploration Basket Study to Investigate the Safety and Tolerability of Subretinally Injected OPGx-BEST1 Administered in Patients with Either Autosomal-Dominant or Autosomal-Recessive BEST1 Disease (Best Vitelliform Macular Dystrophy [BVMD] or Autosomal-Recessive Bestrophinopathy
Spyglass
A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System (78 mcg) used in combination with the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%
Dompe
A 12-Week, Phase 2, Multicenter, Randomized, Double-Masked, VehicleControlled, Parallel Group Study With 2 Weeks of Follow-Up to Evaluate the Efficacy and Safety of DFL24498 0.08% Topical Ophthalmic Solution Versus Vehicle in Participants with Dry Eye Disease
EyeBio
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2mg) in subjects with neovascular age-related macular degeneration (NVAMD)
Abbvie
Study to Evaluate the Safety and Effectiveness of the XEN 63 Glaucoma Gel Stent Using Ab Interno and Ab Externo Implantation Approaches
Harrow
A Phase3, Prospective, Multicenter, Randomized, Parallel-Arm Double-Masked, Placebo-Controlled Study Evaluating the Safety and Efficacy of Triesence for the Treatment of Ocular Inflammation and Pain after Ophthalmic Surgery
CVP Physicians Dayton
Astellas
A NON-INTERVENTIONAL, OBSERVATIONAL STUDY TO EVALUATE TREATMENT PATTERNS AND SAFETY OF AVACINCAPTAD PEGOL (ACP/IZERVAY™) IN ROUTINE CLINICAL PRACTICE IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Retina Vitreous Associates
Not Enrolling Trials Currently
Michigan
Associated Retinal Consultants
Lowry Medical Research Institute
MacTel NHOR: A Natural History Observation and Registry Study of Macular Telangiectasia Type 2
ONL
A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)
Apellis
A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, MASKED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF MULTIDOSE APL-3007 IN COMBINATION WITH SYFOVRE/PEGCETACOPLAN (APL-2) IN PATIENTS DIAGNOSED WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Regeneron
A Phase 1/2a Study of REGN7041 (Anti-CD3 Monoclonal Antibody) in Participants with Active Noninfectious Uveitis Affecting the Posterior Segment.
Abbvie
A Randomized Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration
Kalaris
A Phase 1 Open-Label Clinical Trial To Establish The Safety, Tolerability, Dose Range, And Pharmacokinetic Profile Of Intravitreal Injection Of TH103 In Patients With Neovascular Age-Related Macular Degeneration.
Oakland Ophthalmic Surgery
Apthera
IC-8 Apthera IOL New Enrollment Post Approval Study
Samsara
A prospective, multicenter clinical study of the Implantable Miniature Telescope, Model SING in patients with central vision impairment associated with end-stage age-related macular degeneration (AMD).
Huron
No enrolling trials at this time
New Jersey
Monmouth Retina Consultants
Abbvie
A Randomized Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration.
Apellis
A Phase 2, Randomized, Placebo-Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in combination with Syfovre/Pegcetacoplan (APL-2) in patients diagnosed with Geographic Atrophy secoondary to Age-Related Macular Degeneration.
Institutional Biosafety Committee Review Meeting Minutes
Monday, August 17, 2026
Cincinnati Eye Institute, Cincinnati, OH
Principal Investigator: Robert Sisk, MD
Protocol: Astellas Institute for Regenerative Medicine, 2020-CL-0101
NCT Number: N/A
Meeting Type: Initial Review of Protocol and Site
Title: A Phase 1b, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety,
Tolerability, and Preliminary Efficacy of a Single Subretinal Dose of ASP2020 in
Meeting Minutes
Monday, July 20, 2026
Associated Retinal Consultants, PC, Troy, MI
Principal Investigator: Tamer Mahmoud, MD, PhD
Protocol: AbbVie, Inc., RGX-314-2104
NCT Number: NCT04704921
Meeting Type: Continuing Review of Protocol and Site
Title: A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate
the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
(ATMOSPHERE)
Meeting Minutes
IBC Determination
March 30, 2026
Advarra Institutional Biosafety Committee
Principal Investigator: Konstantin Astafurov
Protocol: PROTO202500115
Meeting Type: Initial Review
Title: A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)
Meeting Minutes
March 18, 2026
Cincinnati Eye Institute
Principal Investigator: Robert Sisk, MD, FACS
Protocol: OPGx-BEST1 DUO-1001: A Phase 1b/2a, Open-Label, Dose-Exploration Basket Study to Investigate the Safety and Tolerability of Subretinally Injected OPGx-BEST1 Administered in Patients with Either Autosomal-Dominant BEST1 Disease (Best Vitelliform Macular Dystrophy [BVMD]) or Autosomal-Recessive Bestrophinopathy (ARB)
Meeting Type: Virtual Platform Teleconference (Remote) Open to the Public
Meeting Minutes
Feb. 6, 2026
Associated Retinal Consultants, PC, Troy, MI
Principal Investigator: Jeremy D. Wolfe, MD
Protocol: AbbVie, Inc., RGX-314-3101
NCT Number: NCT05407636
Meeting Type: Continuing Review of Protocol and Site
Title: A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
Meeting Minutes
Nov. 24, 2025
Principal Investigator: Robert Sisk, M.D.
Protocol: AbbVie, Inc., RGX-314-2104
NCT Number: NCT04704921
Meeting Type: Continuing Review of Protocol and Site
Title: A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
Meeting Minutes
Principal Investigator: Robert Sisk, M.D.
Protocol: AbbVie, Inc., AGTC-RPGR-002
NCT Number: NCT04850118
Meeting Type: Continuing Review of Protocol and Site
Title: A Phase 2/3, Randomized, Controlled, Masked, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Two Doses of AGTC-501, a Recombinant Adeno-associated Virus Vector Expressing RPGR (rAAV2tYF-GRK1-RPGR), Compared to an Untreated Control Group in Male Subjects with X-linked Retinitis Pigmentosa Confirmed by a Pathogenic Variant in the RPGR Gene
Meeting Minutes
Nov. 7, 2025
Associated Retinal Consultants, PC, Troy, MI
Principal Investigator: Jeremy D. Wolfe, MD
Protocol: AbbVie, Inc., M24-528 NCT Number: NCT07007065
Meeting Type: Initial Review of Protocol and Site
Title: Neovascular Age-Related Macular Degeneration (nAMD): A Phase 3b Study of Surabgene Lomparvovec Assessing the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity in a Real-World Context
Meeting Minutes
Nov. 6, 2025
Monmouth Retina Consultants, Monmouth, N.J.
Principal Investigator: Konstantin Astafurov, M.D., Ph.D.
Protocol: RGX-314-3101
NCT Number: NCT05407636
Meeting Type: Annual Study Review
Title: A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT)
Meeting Minutes
Sept. 2, 2025
Cincinnati Eye Institute, Cincinnati, Ohio
Principal Investigator: Robert Sisk, M.D.
Protocol: [REDACTED]
NCT Number: 06864988
Meeting Type: Initial Review
Title: A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of [REDACTED] in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration [REDACTED]
Meeting Minutes
June 27, 2025
Retina Institute of Virginia
Principal Investigator: Tabassian, Ali M.D., Ph.D.
Protocol: AbbVie, Inc., RGX-314-3101
Meeting Type: Annual Review
Title: A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT)
Meeting Minutes
June 17, 2025
John-Kenyon American Eye Institute, New Albany, Ind.
Principal Investigator: Howard Lazarus, M.D.
Protocol: AbbVie, Inc., RGX-314-2104
NCT Number: NCT04704921
Meeting Type: Continuing Review of Protocol and Site
Title: A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
Meeting Minutes
